{"id":"rescue-medications-for-chemotherapy","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Pneumonia"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Fatigue"},{"rate":"1-5%","effect":"Nausea"},{"rate":"1-5%","effect":"Vomiting"},{"rate":"1-5%","effect":"Rash"},{"rate":"1-5%","effect":"Itching"},{"rate":"1-5%","effect":"Pruritus"},{"rate":"1-5%","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's natural defenses to recognize and destroy the cancer cells. This leads to an increase in the body's immune response against the cancer, ultimately resulting in the reduction of tumor size and slowing of cancer progression.","oneSentence":"This drug works by inhibiting the activity of the PD-1 receptor, allowing the immune system to attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:52.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Urothelial carcinoma"},{"name":"Melanoma"},{"name":"Renal cell carcinoma"},{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"},{"name":"Cervical cancer"},{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT05723588","phase":"PHASE2","title":"Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-10-31","conditions":"Tobacco Use Disorder","enrollment":50},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT07272486","phase":"NA","title":"The Use of Virtual Reality and Music Therapy for Hypertensive Urgency","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-08-01","conditions":"Hypertensive Urgency, Primary Hypertension","enrollment":130},{"nctId":"NCT07277153","phase":"PHASE4","title":"Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery.","status":"COMPLETED","sponsor":"Xin Chen","startDate":"2025-10-18","conditions":"Laparoscopic Surgery for Cholecystitis","enrollment":150},{"nctId":"NCT07022990","phase":"NA","title":"Improving Medication Management in World Trade Center Responders","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-04-08","conditions":"Polypharmacy","enrollment":50},{"nctId":"NCT06754657","phase":"PHASE4","title":"CORA-Q15: Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-05-26","conditions":"Arthropathy Shoulder, Pain, Acute, Anesthesia","enrollment":150},{"nctId":"NCT03755414","phase":"PHASE1","title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-04","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes","enrollment":55},{"nctId":"NCT02620046","phase":"PHASE3","title":"A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-15","conditions":"Colitis, Ulcerative, Crohn's Disease","enrollment":746},{"nctId":"NCT06399107","phase":"PHASE1, PHASE2","title":"Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-08-01","conditions":"Sickle Cell Disease, Sickle-Cell Disease With Crisis","enrollment":85},{"nctId":"NCT05293600","phase":"PHASE1, PHASE2","title":"Rescue Pharmacotherapy for OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-01","conditions":"Obstructive Sleep Apnea","enrollment":70},{"nctId":"NCT00596154","phase":"PHASE2","title":"Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-12","conditions":"CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma","enrollment":33},{"nctId":"NCT03599960","phase":"PHASE2","title":"Combination Chemotherapy in Patients With Newly Diagnosed BPDCN","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2019-05-02","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","enrollment":26},{"nctId":"NCT04135937","phase":"PHASE4","title":"Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-11-18","conditions":"Human Immunodeficiency Virus, Smoking","enrollment":12},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT04756713","phase":"PHASE3","title":"Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-11","conditions":"Gestational Trophoblastic Neoplasia, Molar Pregnancy, Gestational Trophoblastic Tumor, Non-Metastatic","enrollment":150},{"nctId":"NCT03161223","phase":"PHASE1, PHASE2","title":"Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2018-05-30","conditions":"Lymphoma, T-Cell","enrollment":148},{"nctId":"NCT00001013","phase":"PHASE3","title":"Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":364},{"nctId":"NCT00001014","phase":"PHASE3","title":"Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":302},{"nctId":"NCT00000714","phase":"PHASE3","title":"An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":""},{"nctId":"NCT04937933","phase":"PHASE4","title":"Effect of Coolant Spray on Traumatic Rib Pain of Geriatric Patients","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2019-10-01","conditions":"Thorax; Fracture, Pain; Thorax, Thoracic, Spine, With Radicular and Visceral Pain","enrollment":101},{"nctId":"NCT02995915","phase":"PHASE4","title":"Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Smoking Cessation, Alcohol Drinking","enrollment":45},{"nctId":"NCT00967499","phase":"PHASE2","title":"Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-07-13","conditions":"Postoperative Nausea and Vomiting","enrollment":239},{"nctId":"NCT00936156","phase":"PHASE2","title":"Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-01","conditions":"Metastatic, Cerebral Primitive Neuroectodermal Tumors","enrollment":68},{"nctId":"NCT04429139","phase":"NA","title":"Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-02-01","conditions":"Retinoblastoma","enrollment":8},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT00798811","phase":"PHASE2","title":"High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2005-09","conditions":"Brain Tumor","enrollment":100},{"nctId":"NCT03149718","phase":"NA","title":"Community Pharmacists and Opioid Misuse","status":"COMPLETED","sponsor":"University of Utah","startDate":"2017-09-15","conditions":"Opioid Misuse","enrollment":46},{"nctId":"NCT00641511","phase":"PHASE2","title":"Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)","status":"WITHDRAWN","sponsor":"Michael E. DeBakey VA Medical Center","startDate":"2008-06","conditions":"Post Traumatic Stress Disorder (PTSD)","enrollment":""},{"nctId":"NCT02420015","phase":"PHASE4","title":"Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-27","conditions":"Schizophrenia, Cigarette Smoking","enrollment":35},{"nctId":"NCT03075163","phase":"PHASE4","title":"Post-Operative Therapy for Nausea or Vomiting","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2016-10-18","conditions":"Vomiting, Nausea","enrollment":300},{"nctId":"NCT01863862","phase":"NA","title":"Organ Preservation in Elderly Patients With Rectal Cancer","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2012-08","conditions":"Rectal Cancer","enrollment":90},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01901848","phase":"PHASE2, PHASE3","title":"CPT and Smoking Cessation","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-12-11","conditions":"Stress Disorders, Post-Traumatic, Smoking","enrollment":69},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT01405924","phase":"PHASE2","title":"Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-25","conditions":"Nausea, Vomiting","enrollment":111},{"nctId":"NCT03571282","phase":"EARLY_PHASE1","title":"Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-06","conditions":"Circumscribed Choroidal Haemangioma","enrollment":50},{"nctId":"NCT02093325","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2014-03","conditions":"Solid Tumor","enrollment":83},{"nctId":"NCT02270788","phase":"PHASE1","title":"Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-02","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT02979548","phase":"PHASE3","title":"Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy","status":"UNKNOWN","sponsor":"Dr Atul Sharma","startDate":"2016-11","conditions":"Chemotherapy Induced Vomiting, Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT01736917","phase":"PHASE2","title":"Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors","status":"COMPLETED","sponsor":"Lawrence Einhorn","startDate":"2013-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":65},{"nctId":"NCT01990079","phase":"NA","title":"Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-12","conditions":"PTSD, Smoking","enrollment":15},{"nctId":"NCT01789710","phase":"NA","title":"Contingency Management for Smoking Cessation in Homeless Smokers","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-01","conditions":"Smoking, Homeless Persons","enrollment":25},{"nctId":"NCT00584766","phase":"PHASE2","title":"Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"1987-10","conditions":"Metastatic Breast Cancer","enrollment":21},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT01172912","phase":"PHASE2","title":"High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2010-10","conditions":"Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor","enrollment":47},{"nctId":"NCT00389766","phase":"PHASE2","title":"High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma","status":"WITHDRAWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2008-07","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00002704","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-01","conditions":"Leukemia","enrollment":156},{"nctId":"NCT00000724","phase":"PHASE3","title":"A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":""},{"nctId":"NCT00179816","phase":"PHASE1, PHASE2","title":"Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors","status":"UNKNOWN","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"1999-04","conditions":"Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma","enrollment":12},{"nctId":"NCT01088022","phase":"PHASE3","title":"Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2010-04","conditions":"Nausea, Vomiting","enrollment":120},{"nctId":"NCT00001016","phase":"PHASE3","title":"A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":""},{"nctId":"NCT00186641","phase":"PHASE2","title":"High Dose Chemotherapy and Autologous Transplant for Breast Cancer","status":"UNKNOWN","sponsor":"Stanford University","startDate":"","conditions":"Graft vs Host Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rescue medications for chemotherapy","genericName":"Rescue medications for chemotherapy","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug works by inhibiting the activity of the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}